MRI and Biomarkers in Prostate Cancer (Multi-IMPROD)

Ivan Jambor

Feb 27, 2019

MRI and Biomarkers in Prostate Cancer (Multi-IMPROD)

PLOS Medicine

DOI

dx.doi.org/10.17504/protocols.io.ynifvce

Ivan Jambor¹

¹Janne Verho, Otto Ettala, Juha Knaapila, Pekka Taimen, Kari T. Syvänen, Aida Kiviniemi, Esa Kähkönen, Ileana Montoya Perez, Marjo Seppänen, Antti Rannikko, Outi Oksanen, Jarno Riikonen, Sanna Mari Vimpeli Tommi Kauko, Harri Merisaari, Markku Kallajoki, Tuomas Mirtti, Tarja Lamminen, Jani Saunavaara, Hannu J. Aronen, Peter J. Boström

Ivan Jambor

DOI: dx.doi.org/10.17504/protocols.io.ynifvce

External link: http://petiv.utu.fi/multiimprod/

Protocol Citation: Ivan Jambor 2019. MRI and Biomarkers in Prostate Cancer (Multi-IMPROD). protocols.io https://dx.doi.org/10.17504/protocols.io.ynifvce

Manuscript citation:

Jambor I,  Verho J,  Ettala O,  Knaapila J,  Taimen P,  Syvänen KT,  Kiviniemi A,  Kähkönen E,  Perez IM,  Seppänen M,  Rannikko A,  Oksanen O,  Riikonen J,  Vimpeli SM,  Kauko T,  Merisaari H,  Kallajoki M,  Mirtti T,  Lamminen T,  Saunavaara J,  Aronen HJ,  Boström PJ, Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial. PLoS Medicine  16(6). doi: 10.1371/journal.pmed.1002813

License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Recruitment Status : Completed

Created: February 27, 2019

Last Modified: February 27, 2019

Protocol Integer ID: 20906

Keywords: IMPROD biparametric MRI, diffusion weighted imaging, prostate cancer, PSA, multi-institutional trial, prostate cancer screening

Abstract

MULTI-IMPROD clinical trial (ClinicalTrials.gov Identifier NCT02241122) is a mutli-institutional validation trial of IMPROD trial (NCT01864135) using the same clinical trial set up, MRI acquisition and reporting system as IMPROD trial. Multi-IMPROD validated at 4 centers the use of high quality rapid 3 Tesla biparametric magnetic resonance imaging (bpMRI), T2-weighted imaging and three separate diffusion-weighted imaging acquisitions, combined with targeted biopsy (TB) for improving risk stratification of men with elevated prostate-specific antigen (PSA) before their first biopsy.

Attachments